Salix v. Cipla: Xifaxan Rifaximin Patent Dispute Resolved by Confidential Settlement
Salix Pharmaceuticals, Bausch Health Ireland, and Alfasigma sued generic manufacturer Cipla Limited in the District of New Jersey over three patents protecting Xifaxan 550 mg rifaximin tablets for IBS-D. The parties resolved the dispute through a confidential settlement and license agreement after 354 days — a resolution timeline consistent with negotiated ANDA litigation outcomes.
Hatch-Waxman rifaximin battle ends in licensed settlement before trial
Filed on 1 November 2024 in the District of New Jersey, this Hatch-Waxman infringement action pitted the Xifaxan commercial consortium — Salix Pharmaceuticals, Inc., Salix Pharmaceuticals, Ltd., Bausch Health Ireland, Ltd., and licensor Alfasigma S.p.A. — against Indian generic manufacturer Cipla Limited. The suit asserted three patents: US8193196B2, US11779571B2, and US11564912B2, all protecting rifaximin 550 mg tablet formulations and their use in treating irritable bowel syndrome with diarrhea (IBS-D) in adults.
The case closed on 21 October 2025 via a stipulated dismissal without prejudice, reflecting a Confidential Settlement and License Agreement signed by both sides. The without-prejudice dismissal, combined with an express license grant, is the hallmark ANDA settlement structure: Cipla likely received a negotiated entry date for its generic rifaximin product, while the plaintiffs preserved patent validity and avoided a potentially invalidating trial outcome. All claims, counterclaims, and affirmative defenses were dropped without costs to either party.
At 354 days, the case resolved considerably faster than the typical ANDA litigation lifecycle, which often runs two to four years before a bench trial. This pace suggests the parties reached commercial alignment relatively early — possibly reflecting the complexity of the three-patent portfolio, the commercial stakes of the branded Xifaxan franchise, and Cipla’s strategic interest in securing a defined U.S. market entry window. The precise licensed entry date and royalty terms remain confidential and cannot be confirmed from the public record.
Filing to Case Settled in 354 days
354 days — faster than the median Hatch-Waxman ANDA trial-to-settlement timeline of ~2–3 years
Confidential license and dismissal: what the settlement structure means for both sides
Stipulated dismissal without prejudice under a license agreement
A without-prejudice dismissal paired with a confidential settlement license is the standard Hatch-Waxman endgame. It means neither party obtained a court ruling on validity or infringement. The patents remain presumptively valid. Cipla retains no estoppel bar, but the license agreement — not court order — now governs its right to commercialise generic rifaximin. The public record does not disclose the licensed entry date or financial terms.
No merits adjudicationSalix and Alfasigma preserve validity and gain a licensed partner
By settling rather than litigating to judgment, Salix and Alfasigma avoided the risk of an adverse validity finding that could have cleared the path for all generic entrants. The confidential license likely grants Cipla a defined entry date, giving the brand side revenue certainty and continued exclusivity until that date. All three asserted patents survive this litigation legally unscathed and remain enforceable against other potential ANDA filers.
Patents intact, entry date negotiatedCipla secures licensed U.S. entry path without invalidity ruling
Cipla’s agreement to dismiss without an invalidity ruling suggests it valued a certain licensed entry date over the uncertain upside of a trial win. Under a typical ANDA settlement license, Cipla likely secured a specific future launch date for its 550 mg rifaximin tablets. Whether Cipla also obtained most-favoured-entry protections — common in multi-defendant ANDA cases — is not publicly disclosed.
Licensed entry path securedThree rifaximin patents remain active threats to subsequent ANDA filers
With Cipla licensed rather than having invalidated the patents, any subsequent generic manufacturer seeking U.S. approval for rifaximin 550 mg faces the full three-patent barrier. US8193196B2, US11779571B2, and US11564912B2 remain listed in the Orange Book and available for assertion. The settlement reinforces the commercial value of the Xifaxan portfolio and raises the cost of entry for the next challenger.
Barrier to entry maintainedFull party and counsel information
| Role | Name | Type | Detail |
|---|---|---|---|
| Plaintiff | Salix Pharmaceuticals, Inc. | Company | Pharmaceutical brand consortium — holders of US8193196B2, US11779571B2, US11564912B2Search in Eureka ↗ |
| Co-Plaintiff | Salix Pharmaceuticals, Ltd. | Company | Search in Eureka ↗ |
| Co-Plaintiff | Bausch Health Ireland, Ltd. | Company | Search in Eureka ↗ |
| Co-Plaintiff | Alfasigma, S.p.A. | Individual | Search in Eureka ↗ |
| Defendant | Cipla Limited | Individual | Cipla Limited — Indian generic pharmaceutical manufacturer seeking U.S. rifaximin market entrySearch in Eureka ↗ |
| Co-Defendant | CIPLA Limited | Individual | Search in Eureka ↗ |
| Plaintiff counsel | Harvey Bartle , IV | Attorney | Counsel for Salix Pharmaceuticals, Inc.Search in Eureka ↗ |
| Plaintiff counsel | JULIE S. GOLDENBERG | Attorney | Counsel for Salix Pharmaceuticals, Inc.Search in Eureka ↗ |
| Plaintiff counsel | KARON N. FOWLER | Attorney | Counsel for Salix Pharmaceuticals, Inc.Search in Eureka ↗ |
| Plaintiff counsel | LIYA LEVIN | Attorney | Counsel for Salix Pharmaceuticals, Inc.Search in Eureka ↗ |
| Plaintiff counsel | MICHAEL T. SIKORA | Attorney | Counsel for Salix Pharmaceuticals, Inc.Search in Eureka ↗ |
| Plaintiff law firm | Morgan, Lewis & Bockius, LLP | Law Firm | Representing Salix Pharmaceuticals, Inc.Search in Eureka ↗ |
| Defendant counsel | Loly G. Tor | Attorney | Counsel for Cipla LimitedSearch in Eureka ↗ |
| Defendant counsel | Peter Louis Giunta | Attorney | Counsel for Cipla LimitedSearch in Eureka ↗ |
| Defendant counsel | WILLIAM E. ANTONIDES , III | Attorney | Counsel for Cipla LimitedSearch in Eureka ↗ |
| Defendant law firm | K&L Gates, LLP | Law Firm | Representing Cipla LimitedSearch in Eureka ↗ |
| Presiding judge | Judge John F. Murphy (EDPA) | Judge | New Jersey District CourtSearch in Eureka ↗ |
Official order — verbatim text
The stipulated dismissal language — ‘dismissed without prejudice and without costs, disbursements, or attorney fees’ — confirms this was a fully negotiated exit from litigation, not a unilateral withdrawal. The explicit reference to a ‘Confidential Settlement and License Agreement’ is legally significant: it means Cipla’s future commercialisation rights flow from contract, not from a court ruling. No infringement or validity finding was made. The patents retain their presumption of validity, and the without-prejudice dismissal leaves open the theoretical possibility of future litigation if either party alleges a breach of the settlement terms.
US8193196B2, US11779571B2 & US11564912B2 — Rifaximin 550 mg and IBS-D treatment patents
The three asserted patents — US8193196B2, US11779571B2, and US11564912B2 — cover different layers of the Xifaxan 550 mg franchise: formulation chemistry, therapeutic use methods for IBS-D, and solid dosage compositions. US8193196B2 is the earliest of the trio, filed under application US11/658702, and likely covers foundational rifaximin polymorphic forms or compositions. The two later patents (applications US17/197561 and US17/892982) represent continuation-family claims that extend protection into formulation and method-of-treatment territory, creating a layered exclusivity wall characteristic of mature brand pharmaceutical portfolios.
Rifaximin is a minimally absorbed, gut-targeted antibiotic with a multi-billion-dollar U.S. franchise anchored by Xifaxan. The multi-patent, multi-applicant structure — with Alfasigma as originator, Salix as U.S. commercial rights holder, and Bausch Health Ireland holding regulatory assets — is a deliberate strategy to maximise litigation leverage and complicate generic entry. For any manufacturer seeking ANDA approval for rifaximin 550 mg, this three-patent stack means facing simultaneous assertions across formulation, composition, and method-of-treatment claims. The Cipla settlement demonstrates that Salix is prepared to litigate and negotiate on all three fronts simultaneously.
Should you run an FTO against US8193196B2, US11779571B2, and US11564912B2?
Any pharmaceutical company developing, manufacturing, or seeking U.S. regulatory approval for rifaximin 550 mg tablets — or IBS-D therapeutic applications of rifaximin — should treat these three patents as active freedom-to-operate risks. The Cipla settlement confirms Salix will enforce this portfolio. The without-prejudice dismissal means no claim was invalidated, and all three patents remain fully enforceable. Formulation scientists, regulatory affairs teams, and business development professionals evaluating rifaximin pipeline assets should conduct independent FTO analysis before filing an ANDA or IND.
PatSnap Eureka’s FTO Search Agent can map each claim of US8193196B2, US11779571B2, and US11564912B2 against your proposed rifaximin formulation or method of treatment, identify prior art relevant to validity challenges, and flag continuation applications that may extend the exclusivity window beyond the nominal expiry dates. With a confidential settlement in place, the next ANDA challenger will face this portfolio without the benefit of Cipla’s litigation record — making early FTO and validity assessment more critical than ever.
Run a freedom-to-operate analysis on US8193196B2 to assess your product’s exposure
Run FTO in Eureka →Similar rifaximin and ANDA pharmaceutical patent cases in the District of New Jersey
Explore comparable Hatch-Waxman ANDA infringement cases involving rifaximin, antibiotic formulation patents, and generic entry disputes litigated in the District of New Jersey.
What this case signals for the rifaximin and ANDA litigation IP landscape
A fast ANDA settlement over three rifaximin patents has implications for every generic manufacturer eyeing the Xifaxan franchise.
Three rifaximin patents survive — and remain enforceable against new ANDA filers
Because the case settled without a validity ruling, US8193196B2, US11779571B2, and US11564912B2 remain presumptively valid and Orange Book-listed. Any generic manufacturer filing a Paragraph IV certification against these patents should expect litigation within the 45-day statutory window. Salix’s willingness to litigate — and settle on its own terms — signals an active enforcement posture.
Settlement pace suggests high commercial stakes drove early resolution
At 354 days, the resolution is faster than the typical ANDA bench trial timeline. This pattern is consistent with both parties preferring commercial certainty: Salix protects near-term brand revenue; Cipla secures a defined U.S. launch window. R&D teams benchmarking IBS-D pipeline assets should factor in the probability of settlement — and the exclusivity runway it buys — when modelling generic entry timelines.
Salix v Cipla — key questions answered
Salix and its co-plaintiffs asserted three patents: US8193196B2, US11779571B2, and US11564912B2. All three relate to rifaximin 550 mg tablets marketed as Xifaxan and their use in treating IBS-D in adult patients. The patents cover overlapping aspects of formulation, composition, and method of treatment.
The case was resolved through a Confidential Settlement and License Agreement. The parties filed a stipulated dismissal without prejudice and without costs on 21 October 2025, approximately 354 days after filing. No court ruling on infringement or patent validity was issued. Cipla’s rights to commercialise generic rifaximin now flow from the confidential license, not a court order.
A without-prejudice dismissal means no merits determination was made. All three asserted patents — US8193196B2, US11779571B2, and US11564912B2 — retain their presumption of validity and remain Orange Book-listed. Salix retains the full right to assert them against any subsequent ANDA filer. Neither party is estopped from raising claims in future litigation arising from a breach of the settlement agreement.
The plaintiff group comprises Salix Pharmaceuticals, Inc. and Salix Pharmaceuticals, Ltd. (U.S. commercial rights holders), Bausch Health Ireland, Ltd. (regulatory and IP holding entity within the Bausch Health group), and Alfasigma S.p.A. (Italian originator and licensor of rifaximin). This multi-entity structure is common in branded pharmaceutical litigation and reflects the layered ownership typical of licensed drug franchises.
Because no patent was invalidated or held unenforceable, all three Xifaxan patents remain active barriers to entry. Any generic manufacturer filing a Paragraph IV ANDA certification for rifaximin 550 mg tablets can expect Salix to initiate litigation within the 45-day statutory window. The Cipla settlement — particularly if it includes a most-favoured-entry clause — may also affect the timing any subsequent settlement could offer to other generic challengers.
PatSnap Eureka searches patents and litigation data to answer instantly.